{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-26-000048","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2026-07-06T20:06:20+00:00","discovered_at":"2026-07-06T20:07:00.305253+00:00","generated_at":"2026-07-06T20:07:08.854534+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Incyte completes $1.25B acquisition of Vega Therapeutics, adding Phase 3 VWD asset VGA039","bullets":["Acquisition adds VGA039, a novel monoclonal antibody in Phase 3 for von Willebrand disease (VWD).","Upfront payment of $1.25B; up to $750M in additional sales milestones for Star Therapeutics.","VGA039 has Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease FDA designations.","Transaction expected to be recorded as a one-time R&D expense in Q3 and full year 2026.","VGA039 is in pivotal Phase 3 VIVID-6 study; potential first once-monthly subcutaneous prophylactic for VWD."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-26-000048","json":"https://secwatch.observer/filing/0000879169-26-000048.json","markdown":"https://secwatch.observer/filing/0000879169-26-000048.md","text":"https://secwatch.observer/filing/0000879169-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000048/0000879169-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000048/incy-20260706.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-06T20:07:08.854534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}